Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers

By Weber J.   Cheinsong-Popov R.   Callow D.   Adams S.   Patou G.   Hodgkin K.   Martin S.   Gotch F.   Kingsman A.  

Vaccine, Vol. 13, Iss. 9, 1995-06 ,pp. : 831-834

Elsevier

Access to resources Recommend Favorite

Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles

By Caparros-Wanderley W.   Clark B.   Griffin B.E.  

Vaccine, Vol. 22, Iss. 3, 2004-01 ,pp. : 352-361

Elsevier

Access to resources Recommend Favorite

Long-term follow-up of hepatitis A vaccination in children

By Chan C.-Y.   Lee S.-D.   Yu M.-I.   Wang Y.-J.   Chang F.-Y.   Lo K.-J.  

Vaccine, Vol. 17, Iss. 4, 1999-02 ,pp. : 369-372

Elsevier

Access to resources Recommend Favorite

Construction of artificial virus-like particles exposing HIV epitopes, and the study of their immunogenic properties

By Karpenko L.I.   Lebedev L.R.   Ignatyev G.M.   Agafonov A.P.   Poryvaeva V.A.   Pronyaeva T.R.   Ryabchikova E.I.   Pokrovsky A.G.   Ilyichev A.A.  

Vaccine, Vol. 21, Iss. 5, 2003-01 ,pp. : 386-392

Elsevier

Access to resources Recommend Favorite

Flt3 ligand and conjugation to IL-1 peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine

By Pisarev V.M.   Parajuli P.   Mosley R.L.   Chavez J.   Zimmerman D.   Winship D.   Talmadge J.E.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2358-2368

Elsevier

Access to resources Recommend Favorite